Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction.

Abstract:

:Adoptive T cell immunotherapy is an evolving technology with the potential of providing a means to safely and effectively target tumor cells for destruction.

journal_name

Cancer Cell

journal_title

Cancer cell

authors

Ho WY,Blattman JN,Dossett ML,Yee C,Greenberg PD

doi

10.1016/s1535-6108(03)00113-2

keywords:

subject

Has Abstract

pub_date

2003-05-01 00:00:00

pages

431-7

issue

5

eissn

1535-6108

issn

1878-3686

pii

S1535610803001132

journal_volume

3

pub_type

杂志文章,评审
  • Directed phenotype switching as an effective antimelanoma strategy.

    abstract::Therapeutic resistance in melanoma and other cancers arises via irreversible genetic, and dynamic phenotypic, heterogeneity. Here, we use directed phenotype switching in melanoma to sensitize melanoma cells to lineage-specific therapy. We show that methotrexate (MTX) induces microphthalmia-associated transcription fac...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2013.05.009

    authors: Sáez-Ayala M,Montenegro MF,Sánchez-Del-Campo L,Fernández-Pérez MP,Chazarra S,Freter R,Middleton M,Piñero-Madrona A,Cabezas-Herrera J,Goding CR,Rodríguez-López JN

    更新日期:2013-07-08 00:00:00

  • Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis.

    abstract::The metastatic process of colorectal cancer (CRC) is not fully understood and effective therapies are lacking. We show that activation of NOTCH1 signaling in the murine intestinal epithelium leads to highly penetrant metastasis (100% metastasis; with >80% liver metastases) in KrasG12D-driven serrated cancer. Transcrip...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2019.08.003

    authors: Jackstadt R,van Hooff SR,Leach JD,Cortes-Lavaud X,Lohuis JO,Ridgway RA,Wouters VM,Roper J,Kendall TJ,Roxburgh CS,Horgan PG,Nixon C,Nourse C,Gunzer M,Clark W,Hedley A,Yilmaz OH,Rashid M,Bailey P,Biankin AV,Campbell

    更新日期:2019-09-16 00:00:00

  • Cancer epigenetics is no Mickey Mouse.

    abstract::Epigenetic changes are the most common alterations in human cancer, but it has been difficult to sort out cause and effect from studies of human tumors. Several recent nonlethal mouse models implicate both hypomethylation and loss of imprinting (LOI) in tumor formation, including a paper in this issue of Cancer Cell s...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2005.09.014

    authors: Feinberg AP

    更新日期:2005-10-01 00:00:00

  • Dragging ras back in the ring.

    abstract::Ras proteins play a major role in human cancers but have not yielded to therapeutic attack. Ras-driven cancers are among the most difficult to treat and often excluded from therapies. The Ras proteins have been termed "undruggable," based on failures from an era in which understanding of signaling transduction, feedba...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/j.ccr.2014.02.017

    authors: Stephen AG,Esposito D,Bagni RK,McCormick F

    更新日期:2014-03-17 00:00:00

  • Impairment of cytoplasmic eIF6 activity restricts lymphomagenesis and tumor progression without affecting normal growth.

    abstract::Eukaryotic Initiation Factor 6 (eIF6) controls translation by regulating 80S subunit formation. eIF6 is overexpressed in tumors. Here, we demonstrate that eIF6 inactivation delays tumorigenesis and reduces tumor growth in vivo. eIF6(+/-) mice resist to Myc-induced lymphomagenesis and have prolonged tumor-free survival...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2011.04.018

    authors: Miluzio A,Beugnet A,Grosso S,Brina D,Mancino M,Campaner S,Amati B,de Marco A,Biffo S

    更新日期:2011-06-14 00:00:00

  • When LMO1 Meets MYCN, Neuroblastoma Is Metastatic.

    abstract::LMO1 is a high-risk neuroblastoma susceptibility gene, but how LMO1 cooperates with MYCN in neuroblastoma tumorigenesis is unclear. In this issue of Cancer Cell, Zhu et al. develop a novel zebrafish model that elucidates a mechanism by which LMO1 and MYCN synergistically initiate neuroblastoma and contribute to metast...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2017.08.014

    authors: Liu Z,Thiele CJ

    更新日期:2017-09-11 00:00:00

  • Alternative and aberrant splicing of MDM2 mRNA in human cancer.

    abstract::MDM2 has been characterized as a protein that binds to and facilitates degradation of the tumor suppressor p53. Interestingly, more than 40 different splice variants of MDM2 transcripts have been identified both in tumors and normal tissues, and the majority of these variants do not contain sequence encoding the p53 b...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/s1535-6108(02)00091-0

    authors: Bartel F,Taubert H,Harris LC

    更新日期:2002-07-01 00:00:00

  • Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model.

    abstract::Malignant astrocytomas are infiltrative and incurable brain tumors. Despite profound therapeutic implications, the identity of the cell (or cells) of origin has not been rigorously determined. We previously reported mouse models based on conditional inactivation of the human astrocytoma-relevant tumor suppressors p53,...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2008.12.006

    authors: Alcantara Llaguno S,Chen J,Kwon CH,Jackson EL,Li Y,Burns DK,Alvarez-Buylla A,Parada LF

    更新日期:2009-01-06 00:00:00

  • Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia.

    abstract::A subset of B cell acute lymphoblastic leukemia (B-ALL) patients will relapse and succumb to therapy-resistant disease. The bone marrow microenvironment may support B-ALL progression and treatment evasion. Utilizing single-cell approaches, we demonstrate B-ALL bone marrow immune microenvironment remodeling upon diseas...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2020.04.015

    authors: Witkowski MT,Dolgalev I,Evensen NA,Ma C,Chambers T,Roberts KG,Sreeram S,Dai Y,Tikhonova AN,Lasry A,Qu C,Pei D,Cheng C,Robbins GA,Pierro J,Selvaraj S,Mezzano V,Daves M,Lupo PJ,Scheurer ME,Loomis CA,Mullighan CG,

    更新日期:2020-06-08 00:00:00

  • Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.

    abstract::Activating mutations in the FLT3 receptor tyrosine kinase occur in 30% of patients with acute myeloid leukemia. Small molecule FLT3 kinase inhibitors show selective antitumor activity in preclinical models. Clinical studies are underway. ...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/s1535-6108(02)00080-6

    authors: Sawyers CL

    更新日期:2002-06-01 00:00:00

  • Vulnerabilities of mutant SWI/SNF complexes in cancer.

    abstract::Cancer genome sequencing efforts have revealed the novel theme that chromatin modifiers are frequently mutated across a wide spectrum of cancers. Mutations in genes encoding subunits of SWI/SNF (BAF) chromatin remodeling complexes are particularly prevalent, occurring in 20% of all human cancers. As these are typicall...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/j.ccr.2014.07.018

    authors: Helming KC,Wang X,Roberts CWM

    更新日期:2014-09-08 00:00:00

  • BRAF inhibitor unveils its potential against advanced melanoma.

    abstract::Unresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, the discovery of BRAF-activating mutations in approximately 50% of human melanomas has provided an attractive therapeutic target. Here, we discuss two recent publications focusing on the mutant BRAF kinase inhibitor PLX4032 tha...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2010.10.001

    authors: Vultur A,Villanueva J,Herlyn M

    更新日期:2010-10-19 00:00:00

  • A New Role for Lyn in the CLL Microenvironment.

    abstract::The role of Lyn, both a positive and a negative regulator of B and myeloid cells, in chronic lymphocytic leukemia (CLL) has not been well characterized. In this issue of Cancer Cell, Nguyen et al. demonstrated that Lyn in macrophages rather than in CLL cells is critical for the malignancy. ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2016.09.018

    authors: Dong S,Byrd JC

    更新日期:2016-10-10 00:00:00

  • Nuclear factor-kappaB: the enemy within.

    abstract::Numerous lines of investigation suggest that nuclear factor NF-kappaB, a proinflammatory transcription factor, could promote tumorigenesis. Various inflammatory agents, carcinogens, tumor promoters, and the tumor microenvironment activate NF-kappaB. NF-kappaB proteins themselves and proteins regulated by it have been ...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/j.ccr.2004.09.003

    authors: Aggarwal BB

    更新日期:2004-09-01 00:00:00

  • H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia.

    abstract::Homeobox domain-containing transcription factors are important regulators of hematopoiesis. Here, we report that increased levels of nonclustered H2.0-like homeobox (HLX) lead to loss of functional hematopoietic stem cells and formation of aberrant progenitors with unlimited serial clonogenicity and blocked differenti...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2012.06.027

    authors: Kawahara M,Pandolfi A,Bartholdy B,Barreyro L,Will B,Roth M,Okoye-Okafor UC,Todorova TI,Figueroa ME,Melnick A,Mitsiades CS,Steidl U

    更新日期:2012-08-14 00:00:00

  • Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity.

    abstract::Slit is a secreted protein known to function through the Roundabout (Robo) receptor as a chemorepellent in axon guidance and neuronal migration, and as an inhibitor in leukocyte chemotaxis. Here we show Slit2 expression in a large number of solid tumors and Robo1 expression in vascular endothelial cells. Recombinant S...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/s1535-6108(03)00164-8

    authors: Wang B,Xiao Y,Ding BB,Zhang N,Yuan Xb,Gui L,Qian KX,Duan S,Chen Z,Rao Y,Geng JG

    更新日期:2003-07-01 00:00:00

  • Determinants of oncogenic transformation in acute promyelocytic leukemia: the hetero-union makes the force.

    abstract::Acute promyelocytic leukemia (APL) is caused by chromosomal translocations that involve the retinoic acid receptor alpha (RAR) and several other genes to yield X-RAR fusion proteins. Unlike wild-type RARs, which require heterodimerization with the retinoid X receptor (RXR) for their function as DNA-binding transcripti...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章,评审

    doi:10.1016/j.ccr.2007.06.012

    authors: Minucci S,Pelicci PG

    更新日期:2007-07-01 00:00:00

  • Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth.

    abstract::Neuropilin-1 (NRP1) guides the development of the nervous and vascular systems. Binding to either semaphorins or VEGF, NRP1 acts with plexins to regulate neuronal guidance, or with VEGFR2 to mediate vascular development. We have generated two monoclonal antibodies that bind to the Sema- and VEGF-binding domains of NRP...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2006.10.018

    authors: Pan Q,Chanthery Y,Liang WC,Stawicki S,Mak J,Rathore N,Tong RK,Kowalski J,Yee SF,Pacheco G,Ross S,Cheng Z,Le Couter J,Plowman G,Peale F,Koch AW,Wu Y,Bagri A,Tessier-Lavigne M,Watts RJ

    更新日期:2007-01-01 00:00:00

  • The RB and p53 pathways in cancer.

    abstract::The life history of cancer cells encompasses a series of genetic missteps in which normal cells are progressively transformed into tumor cells that invade surrounding tissues and become malignant. Most prominent among the regulators disrupted in cancer cells are two tumor suppressors, the retinoblastoma protein (RB) a...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/s1535-6108(02)00102-2

    authors: Sherr CJ,McCormick F

    更新日期:2002-08-01 00:00:00

  • Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling.

    abstract::The genetic mechanisms responsible for increased incidence of lymphoma in immunocompromised individuals have not been fully elucidated. We show that, in a line of TCR transgenic TG-B mice, an insertional mutation in one allele of the Epm2a locus and epigenetic silencing of another led to a high rate of lymphoma with e...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2006.08.008

    authors: Wang Y,Liu Y,Wu C,Zhang H,Zheng X,Zheng Z,Geiger TL,Nuovo GJ,Liu Y,Zheng P

    更新日期:2006-09-01 00:00:00

  • Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors.

    abstract::Loss of p53 is considered to allow progression of colorectal tumors from the adenoma to the carcinoma stage. Using mice with an intestinal epithelial cell (IEC)-specific p53 deletion, we demonstrate that loss of p53 alone is insufficient to initiate intestinal tumorigenesis but markedly enhances carcinogen-induced tum...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2012.11.014

    authors: Schwitalla S,Ziegler PK,Horst D,Becker V,Kerle I,Begus-Nahrmann Y,Lechel A,Rudolph KL,Langer R,Slotta-Huspenina J,Bader FG,Prazeres da Costa O,Neurath MF,Meining A,Kirchner T,Greten FR

    更新日期:2013-01-14 00:00:00

  • Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.

    abstract::We investigated the transcriptional and epigenetic repression of miR-29 by MYC, HDAC3, and EZH2 in mantle cell lymphoma and other MYC-associated lymphomas. We demonstrate that miR-29 is repressed by MYC through a corepressor complex with HDAC3 and EZH2. MYC contributes to EZH2 upregulation via repression of the EZH2 t...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2012.09.003

    authors: Zhang X,Zhao X,Fiskus W,Lin J,Lwin T,Rao R,Zhang Y,Chan JC,Fu K,Marquez VE,Chen-Kiang S,Moscinski LC,Seto E,Dalton WS,Wright KL,Sotomayor E,Bhalla K,Tao J

    更新日期:2012-10-16 00:00:00

  • Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia.

    abstract::The transcription factor Meis1 drives myeloid leukemogenesis in the context of Hox gene overexpression but is currently considered undruggable. We therefore investigated whether myeloid progenitor cells transformed by Hoxa9 and Meis1 become addicted to targetable signaling pathways. A comprehensive (phospho)proteomic ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2017.03.001

    authors: Mohr S,Doebele C,Comoglio F,Berg T,Beck J,Bohnenberger H,Alexe G,Corso J,Ströbel P,Wachter A,Beissbarth T,Schnütgen F,Cremer A,Haetscher N,Göllner S,Rouhi A,Palmqvist L,Rieger MA,Schroeder T,Bönig H,Müller-Tidow C

    更新日期:2017-04-10 00:00:00

  • E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer.

    abstract::Deregulation of E2F1 activity and resistance to TGFbeta are hallmarks of gastric cancer. MicroRNAs (miRNAs) are small noncoding RNAs frequently misregulated in human malignancies. Here we provide evidence that the miR-106b-25 cluster, upregulated in a subset of human gastric tumors, is activated by E2F1 in parallel wi...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2008.02.013

    authors: Petrocca F,Visone R,Onelli MR,Shah MH,Nicoloso MS,de Martino I,Iliopoulos D,Pilozzi E,Liu CG,Negrini M,Cavazzini L,Volinia S,Alder H,Ruco LP,Baldassarre G,Croce CM,Vecchione A

    更新日期:2008-03-01 00:00:00

  • Is NF-kappaB2/p100 a direct activator of programmed cell death?

    abstract::Transcription factor NF-kappaB has been implicated in cancer development due to its ability to upregulate expression of genes with potentially prooncogenic functions, such as cell cycle regulators and antiapoptotic proteins (Karin et al., 2002). A recent report by suggests that a structural motif, a death domain (DD),...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/s1535-6108(02)00213-1

    authors: Häcker H,Karin M

    更新日期:2002-12-01 00:00:00

  • CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.

    abstract::During breast cancer development, increased presence of leukocytes in neoplastic stroma parallels disease progression; however, the functional significance of leukocytes in regulating protumor versus antitumor immunity in the breast remains poorly understood. Utilizing the MMTV-PyMT model of mammary carcinogenesis, we...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2009.06.018

    authors: DeNardo DG,Barreto JB,Andreu P,Vasquez L,Tawfik D,Kolhatkar N,Coussens LM

    更新日期:2009-08-04 00:00:00

  • Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo.

    abstract::A key characteristic of stem cells and cancer cells is their ability to self-renew. To test if Wnt signaling can regulate the self-renewal of both stem cells and cancer cells in the hematopoietic system, we developed mice that lack beta-catenin in their hematopoietic cells. Here we show that beta-catenin-deficient mic...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2007.11.003

    authors: Zhao C,Blum J,Chen A,Kwon HY,Jung SH,Cook JM,Lagoo A,Reya T

    更新日期:2007-12-01 00:00:00

  • The ups and downs of SRC regulation: tumor suppression by Cbp.

    abstract::Tight control of the tyrosine kinase activity of c-Src is critical for regulating its oncogenic potential. In a recent issue of Molecular Cell, Oneyama et al. (2008a) report that the membrane-bound adaptor protein Cbp (also known as PAG) can suppress c-Src-mediated cell transformation and tumorigenesis by binding and ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2008.05.011

    authors: Resh MD

    更新日期:2008-06-01 00:00:00

  • The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.

    abstract::Using a mouse model of human MLL-AF9 leukemia, we identified the lysine-specific demethylase KDM1A (LSD1 or AOF2) as an essential regulator of leukemia stem cell (LSC) potential. KDM1A acts at genomic loci bound by MLL-AF9 to sustain expression of the associated oncogenic program, thus preventing differentiation and a...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2012.03.014

    authors: Harris WJ,Huang X,Lynch JT,Spencer GJ,Hitchin JR,Li Y,Ciceri F,Blaser JG,Greystoke BF,Jordan AM,Miller CJ,Ogilvie DJ,Somervaille TC

    更新日期:2012-04-17 00:00:00

  • Radiotherapy complements immune checkpoint blockade.

    abstract::Adaptive immune resistance ablates effective anti-tumor immune responses. In a recent issue of Nature, Victor and colleagues describe that anti-PD-L1 combats adaptive immune resistance upon localized radiation plus anti-CTLA-4 therapy. The superior activity of radiation and dual immune checkpoint blockade is mediated ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2015.03.015

    authors: Ngiow SF,McArthur GA,Smyth MJ

    更新日期:2015-04-13 00:00:00